Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 28Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Patient Compliance 1Ovarian Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasm Female 1Breast Cancer Metastatic 1Advanced Breast Cancer 1

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6Megestrol Acetate 4niraparib 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × Anastrozole × Clear all
NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡